At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 933 enrolled
Drug / intervention
rizatriptan benzoate (MK0462) +2 moredrug
Likely dose
rizatriptan benzoate (MK0462) 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Compare the Efficacy and Safety of MK0462 5 mg p.o. and Sumatriptan 50 mg p.o. for the Acute Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating rizatriptan benzoate (MK0462), Comparator: sumatriptan, and 1 other intervention for Migraine Headache. Completed, enrolled 933 participants.
Detailed Summary
A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Headache
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 1995
Primary CompletionMay 1996
Study CompletionSep 1996
First PostedMay 2009
TodayJul 2026
First PostedMay 12, 2009
Enrollment StartAug 1, 1995
Primary CompletionMay 1, 1996
Study CompletionSep 1, 1996
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.1 years ago
Interventions
rizatriptan benzoate (MK0462)drug
single dose 5 mg rizatriptan p.o.
Comparator: sumatriptandrug
single dose 50 mg sumatriptan p.o.
Comparator: Placebodrug
Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally